Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

December 15, 2024

Study Completion Date

February 1, 2025

Conditions
Femoral Neck FracturesFemur Head NecrosisHip Fractures
Interventions
DRUG

Liposomal bupivacaine plus bupivacaine

Liposomal bupivacaine is a prolonged-release formulation of the local anesthetic bupivacaine. This intervention involves the administration of liposomal bupivacaine plus bupivacaine as a local anesthetic for the pericapsular nerve group (PENG) block under ultrasound guidance. Liposomal bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This formulation is designed to provide extended pain relief as compared to conventional bupivacaine formulations.

DRUG

Ropivacaine

Ropivacaine is a commonly used local anesthetic in clinical practice, and it serves as the active comparator intervention in this study. Participants in the comparator arm will receive ropivacaine as a local anesthetic for the PENG block under ultrasound guidance.

Trial Locations (1)

430030

Department of Anesthesiology, Tongji Hospital, Tongji Medical College, HUST, Wuhan

All Listed Sponsors
lead

Huazhong University of Science and Technology

OTHER

NCT06565910 - Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) | Biotech Hunter | Biotech Hunter